UPDATE: H.C. Wainwright & Co. Initiates Coverage on Agenus Following 4-Antibody Acquisition
In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Agenus (NASDAQ: AGEN) with a Buy rating and $8.00 price target.
In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Agenus with a BUY rating and a target price of $8. In our opinion, the acquisition of 4-Antibody has propelled the company into the ever exciting field of checkpoint inhibitors. With the addition of 6 lead checkpoint programs, we believe Agenus could soon find itself in the cross hairs of other Pharma/Biotech acquirers. In addition, the company's proprietary personalized platform technology encompassing cancer and infectious disease vaccines as well as the partnered QS-21 program represent significant value drivers for investors.
"With a portfolio of diverse assets, a confluence of milestones anticipated over the next 12-18 months, and a cash position of $85 MM (proforma), we believe Agenus represents an undervalued player with significant upside for the long-term investor.”
Agenus closed on Friday at $3.88.
Latest Ratings for AGEN
|Mar 2016||Maxim Group||Upgrades||Hold||Buy|
|Mar 2016||JMP Securities||Maintains||Market Outperform|
|Oct 2015||Maxim Group||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.